A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study to Evaluate the Effect of Tesaglitazar 1 mg once daily on the Pharmacokinetics of Metformin Following Addition of Tesaglitazar to Metformin Treatment twice daily in Patients with Type 2 Diabetes

Registry ID

EUCTR2005-004032-48

Source registry

EUCTR

Status

Prematurely Ended

Phase

PHASE2

Sponsor

AstraZeneca AB

Start date

2006-01-22

Completion date

2007-01-09

Last update

2026-08-16

Conditions

• Type II Diabetes Mellitus

Summary

To compare the effect of 1 mg tesaglitazar once daily versus placebo once daily given as add?on therapy to metformin on the steady state exposure (AUCss) of metformin in patients with type 2 diabetes with a serum creatinine within normal range and having CrCL>70 mL/min or CrCL≤70 to ≥50mL/min, by assessment after a 12-week randomized treatment period.

Locations

• , , Sweden

Related clinical trials

• The GRoceries Aimed at Increasing Nutrition Study
• A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus
• cfMSC Therapy for Diabetes
• Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus
• Study to Evaluate if Exposure to Drug is Impacted in Participants With Renal Insufficiency
• Real World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in T2DM Patients - EASE Study

View on source registry